Hatteras Venture Partners has announced that it has named Sir Andrew Witty a Venture Partner. He will primarily focus on the strategic positioning of Hatteras and its portfolio companies in the ever-changing global health care industry. In addition, he will provide leadership counsel to Hatteras’ portfolio companies.

Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, N.C., focused on seed and early stage opportunities in biopharmaceuticals, medical devices, diagnostics, healthcare IT and related opportunities in human medicine

Bob Ingram, General Partner of Hatteras Venture Partners said, “We are thrilled to welcome Andrew to Hatteras Venture Partners. He brings unparalleled strategic insights and extensive industry experience to the firm and to our portfolio of emerging companies. Having had the pleasure of serving as Andrew’s mentor when I was CEO of Glaxo, it is hard to fully express my pride in having him join our dynamic team of company builders.”

He is also Chancellor of the University of Nottingham in England and serves on the boards of UnitedHealth Group and G1 Therapeutics, Inc. He was Chief Executive Officer of GlaxoSmithKline, plc (GSK) from 2008 until he retired in 2017.

He joined GSK in 1985 and served in various senior roles in the UK, the U.S., South Africa and Singapore. In 2012, Mr. Witty was knighted for services to the economy and the UK pharmaceutical industry.

Andrew commented, “Joining Hatteras gives me an exciting new opportunity to nurture amazing science for the benefit of patients. The firm has an outstanding track record of finding novel science in the halls of academia and translating that science into successful companies. I cannot think of a better objective in the evolving healthcare environment than capitalizing this kind of innovation.”